Advancements in Biologic Therapies for Pyoderma Gangrenosum

Created using ChatSlide

This overview examines biologic treatments for pyoderma gangrenosum, a chronic neutrophilic ulcerative skin disease. It reviews successful adalimumab use, other anti-TNF agents such as certolizumab and golimumab, and case-based evidence for ustekinumab and secukinumab. Interleukin-1-targeting therapies, including canakinumab and anakinra, are also discussed across refractory, inflammatory bowel disease-associated, IgA-associated, PASH and PAPA syndrome cases. Given the predominantly case-...